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Background:  Admission  glucose  levels  have  proven  to be  a predictor  in patients  with  acute  myocardial
infarction  and elevated  glycosylated  hemoglobin  A1c  (HbA1c)  is  associated  with  an  increased  risk  of
cardiovascular  disease,  even  in patients  without  diabetes.  However,  the  effect  of both  admission  glucose
and  HbA1c  levels  on clinical  outcomes  in non-diabetic  patients  with  acute  coronary  syndrome  (ACS)  has
not been  fully  elucidated.  We  evaluated  the  combined  effect  of  admission  glucose  and  HbA1c  values
on  long-term  clinical  outcomes  in  non-diabetic  patients  with  ACS  treated  with  percutaneous  coronary
intervention  (PCI).
Methods and  results:  This  was  an  observational  study  of 452  consecutive  non-diabetic  patients  with  ACS
who  underwent  PCI between  January  1997  and December  2006.  The  patients  were  assigned  to  four
groups  according  to the  median  values  of admission  glucose  and  HbA1c.  The  primary  endpoint  compris-
ing  a  composite  of  all-cause  death  and  non-fatal  MI  was  compared  among  the  four groups.  The  primary
endpoint  occurred  in  13.3%  of the  participants  during  a  median  follow-up  period  of 4.7  years.  The cumula-
tive  incidence  rate  of primary  endpoint  signiﬁcantly  differed  among  the  groups  (p = 0.048).  Multivariable
Cox  regression  analysis  showed  that the  combination  of  elevated  admission  glucose  and  HbA1c  was
independently  associated  with  long-term  clinical  outcomes.
Conclusions:  Combined  admission  glucose  and  HbA1c  values  were  independently  associated  with  clinical
outcomes  in  non-diabetic  patients  with  ACS treated  with  PCI.
3  Jap© 201
ntroduction
Hyperglycemia on admission in patients with acute myocardial
nfarction (AMI) is a negative predictor of short- and long-term clin-
cal outcomes [1–5]. Hyperglycemia is also associated with poor
linical outcomes among non-diabetic patients and the risk of mor-
ality is higher in hyperglycemic patients without diabetes than
hose with diabetes [6–11]. Glycosylated hemoglobin A1c (HbA1c)
s a marker of long-term glycemic control and elevated HbA1c
s associated with an increased risk of cardiovascular diseases in
atients with diabetes [12]. Moreover, HbA1c is also associated
ith all-cause mortality and cardiovascular disease even in the
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absence of diabetes [13,14]. Both admission glucose and HbA1c
values are associated with clinical outcomes in patients with AMI
[15]. However, the combined effect of admission glucose and HbA1c
on clinical outcomes in an Asian population with acute coronary
syndrome (ACS) remains unknown. Therefore, we evaluated the
combined effect of admission glucose and HbA1c values on long-
term clinical outcomes in non-diabetic patients with ACS treated
with percutaneous coronary intervention (PCI).
Methods
Study populationThis observational study analyzed consecutive non-diabetic
patients with ACS who  were treated with PCI at Juntendo University
Hospital (Tokyo, Japan) between January 1997 and December 2006.
The patients were assigned to four groups according to a median
vier Ltd. All rights reserved.
R. Naito et al. / Journal of Cardiology 63 (2014) 106–111 107
F cutive
D ntion
a
N
o
a
p
G
(
(
w
C
n
c
r
p
t
i
D
m
d
n
(
S
i
f
P
i
d
a
c
(
(
s
t
d
c
t
d
o
R
(ig. 1. Flow chart of study population. The study population included 452 conse
ecember 2006. ACS, acute coronary syndrome; PCI, percutaneous coronary interve
dmission glucose value of 120 mg/dL and HbA1c expressed as a
ational Glycohemoglobin Standardization Program (NGSP) value
f 5.6%. Groups 1 and 4 comprised patients with lower and higher
dmission levels of both components, respectively, Group 2 com-
rised those with lower admission glucose and higher HbA1c, and
roup 3 comprised higher admission glucose and lower HbA1c
Fig. 1). Demographic data including age, gender, body mass index
BMI), coronary risk factors, medication use, and comorbidities
ere collected.
linical outcomes
The primary endpoint was a composite of all-cause death and
on-fatal MI.  Information regarding the clinical outcomes was
ollected during clinical visits, telephone interviews, or from the
eferring physician. Our institutional review board approved the
rotocol of this study, which was performed in accordance with
he principles established in the Declaration of Helsinki and our
nstitutional ethics policy.
eﬁnitions
We  deﬁned ACS as unstable angina pectoris (UAP), non-ST seg-
ent elevation myocardial infarction (NSTEMI), or STEMI. UAP was
eﬁned as having angina at rest or in an accelerating pattern with
egative cardiac biomarkers, with or without electrocardiogram
ECG) changes indicative of myocardial ischemia (for example,
T segment depression, or transient elevation, or new T wave
nversion). Myocardial infarction was deﬁned as an increase (≤2-
old) in serum creatine kinase (CK) and troponin T positivity.
atients were considered non-diabetic if they met  the follow-
ng criteria: (i) their medical records did not include a history of
iabetes; (ii) they were not under treatment with anti-diabetic
gents or insulin; (iii) they had HbA1c (NGSP) values < 6.5%. We
onverted HbA1c [Japan Diabetes Society (JDS)] values to HbA1c
NGSP) units using the following equation: NGSP (%) = 1.02 × JDS
%) + 0.25% [16]. Hypertension was deﬁned as systolic blood pres-
ure ≥ 140 mmHg  and diastolic blood pressure ≥ 90 mmHg  or under
reatment with anti-hypertensive medications. Dyslipidemia was
eﬁned as triglyceride levels ≥ 150 mg/dL, low-density lipoprotein
holesterol levels ≥ 140 mg/dL, high-density lipoprotein choles-
erol levels < 40 mg/dL, or under treatment for dyslipidemia. We
eﬁned current smokers as individuals who smoked at the time
f admission or had quit within one year before the study period.
enal failure was deﬁned as an estimated glomerular ﬁltration rate
eGFR) of <60 mL/min/1.73 m2 calculated using the modiﬁcation of non-diabetic patients with ACS who underwent PCI between January 1997 and
; AG, admission glucose level; HbA1c, glycosylated hemoglobin A1c.
diet in renal disease equation modiﬁed with a Japanese coefﬁcient
using baseline serum creatinine [17].
Statistical analysis
Continuous variables are expressed as means with standard
deviation. Categorical variables are expressed as counts and ratios
(%). Continuous variables were compared using a one-way analy-
sis of variance followed by post hoc analysis using Dunnett’s test
for multiple comparisons. Group 1, which comprised patients with
lower admission glucose and HbA1c values, served as a control
group in the post hoc analysis. Categorical variables were com-
pared using the 2 test or Fisher’s exact probability test. Unadjusted
cumulative event rates were estimated using the Kaplan–Meier
method and compared among groups using the log-rank test. Haz-
ard ratios and 95% conﬁdence intervals for each variable were
calculated using a Cox proportional hazards model. Predictors of
long-term clinical outcomes were identiﬁed using a multivariable
Cox regression analysis. Variables with p < 0.1 in the univariable
Cox regression analysis were included in the multivariable model. A
value of p < 0.05 was considered to indicate statistical signiﬁcance.
All data were analyzed using JMP  version 9.0 for Windows (SAS
Institute, Cary, NC, USA).
Results
We analyzed data from 452 consecutive non-diabetic patients
with ACS who  underwent PCI from January 1997 to December
2006 over a median follow-up period of 4.7 (interquartile range,
2.2–7.5) years. The baseline characteristics of the patients are
shown in Table 1. Only the prevalence of dyslipidemia and prior
PCI signiﬁcantly differed among the groups. Peak CK values and the
prevalence of STEMI were higher and left ventricular ejection frac-
tion (LVEF) was lower in Groups 3 and 4 than in Group 1 (Table 2).
The prevalence of multi-vessel coronary disease (MVD) was higher
in Groups 2 and 4, which included patients with higher HbA1c
values. The primary endpoint occurred in 13.3% of the study partic-
ipants during the follow-up period. The rates of all-cause, cardiac,
and non-cardiac deaths were 10.6%, 4.4%, and 6.2%, respectively,
whereas that of non-fatal MI  was 3.5% (Table 3). The cumulative
incidence of the primary endpoint signiﬁcantly differed among the
groups (log-rank test, p = 0.048; Fig. 2). Group 4 (elevated admis-
sion glucose and HbA1c values), age, gender, BMI, LVEF, eGFR, Hb,
statin use, and MVD  were associated with all-cause mortality and
non-fatal MI  in the univariable Cox regression analysis. Elevated
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Table  1
Baseline characteristics.
Group 1
(N = 113)
both lower
Group 2
(N = 114)
higher HbA1c
Group 3
(N = 108)
higher AG
Group 4
(N = 117)
both higher
p-Value
Age 62.2 ± 11.5 63.8 ± 11.6 65.0 ± 11.3 65.7 ± 11.7 0.1
Male,  n (%) 102 (89.5) 94 (82.5) 83 (77.6) 92 (78.6) 0.07
BMI,  kg/m2 23.8 ± 3.9 24.0 ± 3.3 24.0 ± 3.6 23.6 ± 3.5 0.7
Hypertension, n (%) 65 (57.0) 76 (66.7) 70 (65.4) 69 (59.0) 0.3
Dyslipidemia, n (%) 63 (55.3) 78 (68.4) 44 (41.1) 68 (58.6) <0.001
Smoking, n (%) 42 (36.8) 29 (25.4) 35 (32.7) 27 (23.1) 0.08
Family  history, n (%) 32 (28.1) 28 (24.6) 30 (28.0) 32 (27.4) 0.9
Renal  dysfunction, n (%) 26 (23.6) 27 (24.6) 27 (26.5) 30 (27.8) 0.9
Hemodialysis, n (%) 1 (1.5) 2 (3.3) 4 (7.1) 1 (1.6) 0.3
Prior  MI,  n (%) 7 (6.1) 12 (10.5) 4 (3.7) 14 (12.0) 0.08
Prior  PCI, n (%) 14 (12.3) 25 (21.9) 3 (2.8) 11 (11.7) <0.001
Prior  CABG, n (%) 4 (3.5) 7 (6.1) 0 (0) 7 (6.0) 0.06
AG, admission glucose; HbA1c, hemoglobin A1C; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary bypass graft.
Table  2
Clinical characteristics.
Group 1
(N = 113)
both lower
Group 2
(N = 114)
higher HbA1c
Group 3
(N = 108)
higher AG
Group 4
(N = 117)
both higher
p-Value
SBP, mmHg 135.6 ± 20.4 135.7 ± 27.6 134.3 ± 22.7 131.1 ± 27.6* 0.5
DBP,  mmHg 74.4 ± 11.7 73.9 ± 14.5 75.0 ± 14.0 73.6 ± 15.8 0.9
LDL-C, mg/dL 116.6 ± 35.6 120.9 ± 29.5 120.0 ± 29.0 119.5 ± 39.5 0.8
HDL-C, mg/dL 46.2 ± 14.5 44.2 ± 12.3 43.9 ± 10.1 45.1 ± 11.0 0.5
TG,  mg/dL 107.7 ± 58.2 122.2 ± 52.3 114.1 ± 68.0 120.4 ± 95.9 0.4
Hb,  g/dL 13.6 ± 1.9 13.5 ± 1.7 13.7 ± 1.7 13.8 ± 2.0 0.7
AG,  mg/dL 102.0 ± 11.8 104.7 ± 9.7 147.7 ± 28.6* 160.9 ± 48.6* <0.001
HbA1c, % 4.8 ± 0.4 5.5 ± 0.2* 4.9 ± 0.2 5.5 ± 0.2* <0.001
LVEF,  % 62.0 ± 13.8 60.4 ± 12.4 55.6 ± 12.1* 55.1 ± 14.2* <0.001
BNP,  pg/mL 196.7 ± 75.1 133.1 ± 66.4 298.5 ± 73.1 213.7 ± 58.2 0.4
CRP,  mg/dL 0.98 ± 2.3 1.3 ± 2.3 1.5 ± 2.9 0.6 ± 1.8 0.07
eGFR,  mL/min/1.73 m2 74.4 ± 21.1 71.3 ± 19.0 77.1 ± 24.3 75.2 ± 21.0 0.2
Creatine kinase, U/L (maximum) 1100.0 ± 1667.3 690.9 ± 1216.9 2288.6 ± 2040.0* 2522.0 ± 2559.0* <0.001
Medication, n (%)
Statin 53 (46.5) 53 (46.5) 38 (35.5) 42 (36.2) 0.2
ACE-I/ARB 71 (62.3) 75 (65.8) 81 (75.7) 83 (71.6) 0.1
-Blocker 46 (40.4) 42 (36.8) 42 (39.3) 53 (45.7) 0.6
Culprit vessel, n (%) 0.2
LAD  61 (53.5) 57 (50.0) 55 (51.9) 58 (50.0)
LCX  14 (12.3) 22 (19.3) 19 (17.9) 12 (10.3)
RCA  35 (30.7) 31 (27.2) 32 (30.2) 40 (34.2)
LMT  0 (0) 0 (0) 0 (0) 2 (1.7)
Multivessel disease, n (%) 46 (40.4) 58 (50.9) 33 (30.8) 52 (44.4) 0.02
Type  of ACS, n (%) <0.001
UAP  47 (41.2) 39 (34.2) 8 (7.8) 18 (15.5)
NSTEMI 21 (18.4) 26 (22.8) 19 (17.9) 20 (17.2)
STEMI  46 (40.4) 49 (43.0) 79 (74.5) 78 (67.2)
SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; TG, triglyceride; AG,
admission glucose; HbA1c, hemoglobin A1C; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular
ﬁltration rate; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LAD, left anterior descending artery; LCX, left circumﬂex artery; RCA, right
coronary artery; LMT, left main trunk; ACS, acute coronary syndrome; UAP, unstable angina pectoris; (N)STEMI, (non-)ST elevation myocardial infarction.
* Statistically signiﬁcant value calculated by Dunnett’ s test was marked with asterisk.
Table 3
Long-term clinical events.
Group 1 (N = 113)
lower AG, lower HbA1c
Group 2 (N = 114)
lower AG, higher HbA1c
Group 3 (N = 108)
higher AG, lower HbA1c
Group 4 (N = 117)
higher AG, higher HbA1c
All-cause death 8 (7.0) 10 (8.8) 9 (8.4) 18 (15.7)
CVD  2 (1.8) 3 (2.6) 5 (4.7) 10 (8.6)
Non-CVD 6 (5.3) 7 (6.1) 4 (3.7) 8 (6.8)
Non-fatal MI 2 (1.8) 2 (1.8) 5 (4.7) 8 (6.8)
AG, admission glucose; HbA1c, hemoglobin A1C; CVD, cardiovascular disease; MI,  myocardial infarction.
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Fig. 2. Kaplan–Meier curves for all-cause death and non-fatal MI. The cumula-
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I,  myocardial infarction; AG, admission glucose level; HbA1c, glycosylated
emoglobin A1c.
dmission glucose and HbA1c values remained signiﬁcant after
djustment for variables (Table 4).
iscussion
The present study demonstrated that elevated admission glu-
ose combined with HbA1c values were associated with poor
ong-term clinical outcomes in non-diabetic patients with ACS
reated with PCI. The association remained signiﬁcant even after
djustment for other independent variables.
Hyperglycemia on admission is considered to represent a stress
esponse to acute diseases whereas there remains a possibility
hat hyperglycemia is a reﬂection of impaired glucose tolerance.
he prognostic value of admission hyperglycemia for diabetic
atients with AMI has been established [1,2,4,5]. Ishihara et al.
dentiﬁed admission hyperglycemia as a predictor of in-hospital
ortality after AMI  in an Asian population [3]. Moreover, the risk
f mortality is higher in non-diabetic patients with hyperglycemia
han in diabetic patients [6–11]. The value of HbA1c is related to
able 4
nivariable and multivariable Cox regression analysis for all-cause death and non-fatal m
Univariable 
HR 95% CI 
Age, years 1.09 1.06–1.12 
Male  gender 0.79 0.44–1.53 
Hypertension, yes 1.12 0.67–1.94 
Dyslipidemia, yes 0.84 0.50–1.40 
BMI, kg/m2 0.85 0.79–0.92 
LVEF,  % 0.96 0.94–0.98 
Hb,  g/dL 0.77 0.68–0.87 
eGFR,  mL/min/1.73 m2 0.98 0.96–0.99 
Statin, yes 0.45 0.24–0.80 
CRP  1.03 0.92–1.13 
STEMI 1.43 0.85–2.50 
Creatine kinase, U/L (maximum) 1.0 0.99–1.0001 
Multivessel disease, yes 1.76 1.06–2.96 
HbA1c and AG (Group 1 as reference)
Group 2 (higher HbA1c) 1.61 0.71–3.86 
Group 3 (higher AG) 1.69 0.74–4.06 
Group 4 (both higher) 2.77 1.32–6.31 
R, hazard ratio; 95% CI, 95% conﬁdence interval; BMI, body mass index; LVEF, left ventric
RP,  C-reactive protein; STEMI, ST-elevation myocardial infarction; AG, admission glucoslogy 63 (2014) 106–111 109
risk for cardiovascular disease in patients with diabetes [12] and
it is signiﬁcantly associated with all-cause mortality and cardio-
vascular disease, even in non-diabetic patients [13,14]. A recent
report showed an association between both admission glucose and
HbA1c, and a poor prognosis in non-diabetic patients with AMI
[15]. That study found a 10% mortality rate during a mean follow-up
period of 3.3 years and their multivariable analysis demonstrated
that elevated HbA1c was associated with long-term mortality (HR
1.2, 95% CI 1.0–1.3, p < 0.01). The present study differed from the
previous reports in that we determined the combined effect of
high admission glucose and HbA1c values on long-term clinical
outcomes in non-diabetic Asian patients with ACS.
Several potential mechanisms might explain our ﬁndings.
Hyperglycemia might have disturbed endothelial function through
a reduction in the release of nitric oxide and increased superoxide
production in vessel walls [18–21]. Higher serum glucose increases
vascular smooth muscle cell proliferation and migration [20,22].
These phenomena could lead to atherosclerosis via endothelial
dysfunction. Hyperglycemia is a reﬂection of impaired insulin
secretion that is related to lipolysis and increase of circulating free
fatty acids [1]. An excess of free fatty acids has toxicity to ischemic
myocardium through an increase of myocardial oxygen consump-
tion, resulting in a development of ventricular arrhythmias and
impaired myocardial contractility [23]. Thus, it is conceivable
that admission hyperglycemia could be a negative prognostic
factor among patients with cardiovascular diseases. In fact, 30-day
mortality was  signiﬁcantly higher in our study population with
higher admission glucose levels (HR 1.01, 95% CI 1.001–1.020,
p = 0.035). This population had higher peak CK levels, a higher
prevalence of STEMI and reduced LVEF, which might have affected
the clinical outcomes. Previous reports that have demonstrated
the prognostic impact of peak CK and reduced LVEF on clinical
outcomes in patients with MI  [24–28] could support our ﬁndings.
We identiﬁed a relationship between admission HbA1c and MVD,
which is a predictor of poor clinical outcomes in patients with MI
[29–31]. Therefore, the high prevalence of MVD  could be associated
with poor clinical outcomes in patients with higher admission
HbA1c values. Elevated HbA1c has been reported to be associated
with the new onset of diabetes and future cardiovascular diseases
in a non-diabetic general population [14]. Therefore, our study
population with both higher admission glucose and HbA1c might
have had glucose dysmetabolism with a high possibility of overt
yocardial infarction.
Multivariable
p-Value HR 95% CI p-Value
<0.0001 1.07 1.03–1.10 <0.0001
0.47 2.14 1.06–4.63 0.03
0.67
0.50
<0.0001 0.92 0.84–0.99 0.04
<0.0001 0.97 0.95–0.99 0.005
<0.0001 0.81 0.67–0.96 0.02
0.006 0.99 0.98–1.01 0.29
0.006 0.77 0.39–1.45 0.43
0.5
0.18
0.14
0.03 1.72 0.98–3.07 0.06
0.26 1.92 0.81–4.88 0.14
0.21 1.93 0.79–4.99 0.15
0.006 2.65 1.17–6.58 0.02
ular ejection fraction; Hb, hemoglobin; eGFR, estimated glomerular ﬁltration rate;
e level.
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iabetes, although we did not have data regarding a prevalence of
vert diabetes during the follow-up period.
imitations
The present study has several limitations. First, this was  a single-
enter observational study including a relatively small sample size.
econd, they did not undergo the oral glucose tolerance test (OGTT)
o diagnose diabetes mellitus. Since we classiﬁed patients as non-
iabetes with the criteria described in the Methods section, patients
ith undiagnosed diabetes might have been misclassiﬁed as non-
iabetic. In addition, there were no considerations about impaired
lucose tolerance or postprandial hyperglycemia which has been
ssociated with increased risk for coronary artery disease [32,33],
ecause we did not perform OGTT. Third, speciﬁc agents such as cat-
cholamines that could affect glucose metabolism might be admin-
stered in a part of the study population. In addition, we  did not aim
o clarify the occurrence of diabetes mellitus among the patients
uring the study period. Moreover, patients with higher admis-
ion glucose and HbA1c did not undergo deﬁnite intervention to
reat hyperglycemia. Thus, the signiﬁcance of glycemic control for
ong-term clinical outcomes in this population was  not elucidated.
onclusions
The combination of high admission glucose and HbA1c levels
as signiﬁcantly associated with poor long-term clinical outcomes
n non-diabetic patients with ACS treated with PCI. Careful obser-
ation might be required for the early detection of overt diabetes
ellitus in such patients. Further study is needed to elucidate
peciﬁc therapeutic strategies to prevent cardiovascular events
ccurring in non-diabetic patients with ACS who have elevated
dmission glucose and HbA1c values.
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